Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362586919> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4362586919 endingPage "S118" @default.
- W4362586919 startingPage "S117" @default.
- W4362586919 abstract "Malignant pleural mesothelioma (MPM) has a very poor prognosis: 50% of the patients die within 12 months after starting first-line treatment and no improvement of survival has been reached with second-line treatment. To date, data available on drug screening for mesothelioma is very limited and was only performed using established cell lines. We previously showed that these cell lines have a highly different transcriptomic profile when compared to fresh tumors while patient-derived cell lines most closely resemble the profile of the corresponding cancers. Patient-derived cell lines were generated from digested fresh tumor specimens and characterised by RNA sequencing, whole exome sequencing and histological analysis. A cell viability assay was established for four patient-derived cell lines and a healthy control. A drug screen using a set of 6’500 chemical compounds including Food and Drug Administration (FDA)-approved drugs and candidates in clinical development was performed. Approximately 1000 molecules were considered as hits during the primary screen and dose response curves were performed using 120 selected hits based on viability inhibition potential, previous data on inactivity in mesothelioma and approval status of drugs. A final selection of promising drugs was made after this screen for testing on additional cell lines to understand their mode of action. Calculating dose response curves revealed 11 promising drugs to be repurposed in mesothelioma including anthelmintics, antibiotics, statins, CDC-, HDAC- and NF-kB inhibitors with IC50 s being significantly lower in malignant cell lines compared to healthy cells. To validate the viability inhibiting potential of these drugs, 21 additional MPM cell lines were screened and revealed Regorafenib, Rigosertinib and NSC663284 as most potent candidates for further inVitro and inVivo analysis. Here, we could demonstrate that a high-throughput drug repurposing screen can be an effective tool to find new treatment candidates for MPM. Currently, further validation of the three promising drug candidates is ongoing and will reveal the full potential of repurposing drugs in mesothelioma." @default.
- W4362586919 created "2023-04-06" @default.
- W4362586919 creator A5002066247 @default.
- W4362586919 creator A5003753570 @default.
- W4362586919 creator A5011312485 @default.
- W4362586919 creator A5024957431 @default.
- W4362586919 creator A5031600057 @default.
- W4362586919 creator A5043902170 @default.
- W4362586919 creator A5067090863 @default.
- W4362586919 creator A5079909675 @default.
- W4362586919 creator A5090624108 @default.
- W4362586919 date "2023-04-01" @default.
- W4362586919 modified "2023-09-30" @default.
- W4362586919 title "137P Repurposing drug screen of patient-derived malignant pleural mesothelioma cells reveals potential anti-cancer activity" @default.
- W4362586919 doi "https://doi.org/10.1016/s1556-0864(23)00392-1" @default.
- W4362586919 hasPublicationYear "2023" @default.
- W4362586919 type Work @default.
- W4362586919 citedByCount "0" @default.
- W4362586919 crossrefType "journal-article" @default.
- W4362586919 hasAuthorship W4362586919A5002066247 @default.
- W4362586919 hasAuthorship W4362586919A5003753570 @default.
- W4362586919 hasAuthorship W4362586919A5011312485 @default.
- W4362586919 hasAuthorship W4362586919A5024957431 @default.
- W4362586919 hasAuthorship W4362586919A5031600057 @default.
- W4362586919 hasAuthorship W4362586919A5043902170 @default.
- W4362586919 hasAuthorship W4362586919A5067090863 @default.
- W4362586919 hasAuthorship W4362586919A5079909675 @default.
- W4362586919 hasAuthorship W4362586919A5090624108 @default.
- W4362586919 hasBestOaLocation W43625869191 @default.
- W4362586919 hasConcept C103637391 @default.
- W4362586919 hasConcept C121608353 @default.
- W4362586919 hasConcept C126322002 @default.
- W4362586919 hasConcept C142724271 @default.
- W4362586919 hasConcept C2777407522 @default.
- W4362586919 hasConcept C2780035454 @default.
- W4362586919 hasConcept C502942594 @default.
- W4362586919 hasConcept C53227056 @default.
- W4362586919 hasConcept C54355233 @default.
- W4362586919 hasConcept C71924100 @default.
- W4362586919 hasConcept C81885089 @default.
- W4362586919 hasConcept C86803240 @default.
- W4362586919 hasConcept C98274493 @default.
- W4362586919 hasConceptScore W4362586919C103637391 @default.
- W4362586919 hasConceptScore W4362586919C121608353 @default.
- W4362586919 hasConceptScore W4362586919C126322002 @default.
- W4362586919 hasConceptScore W4362586919C142724271 @default.
- W4362586919 hasConceptScore W4362586919C2777407522 @default.
- W4362586919 hasConceptScore W4362586919C2780035454 @default.
- W4362586919 hasConceptScore W4362586919C502942594 @default.
- W4362586919 hasConceptScore W4362586919C53227056 @default.
- W4362586919 hasConceptScore W4362586919C54355233 @default.
- W4362586919 hasConceptScore W4362586919C71924100 @default.
- W4362586919 hasConceptScore W4362586919C81885089 @default.
- W4362586919 hasConceptScore W4362586919C86803240 @default.
- W4362586919 hasConceptScore W4362586919C98274493 @default.
- W4362586919 hasIssue "4" @default.
- W4362586919 hasLocation W43625869191 @default.
- W4362586919 hasOpenAccess W4362586919 @default.
- W4362586919 hasPrimaryLocation W43625869191 @default.
- W4362586919 hasRelatedWork W1980001478 @default.
- W4362586919 hasRelatedWork W2081773521 @default.
- W4362586919 hasRelatedWork W2399140686 @default.
- W4362586919 hasRelatedWork W2755212028 @default.
- W4362586919 hasRelatedWork W2886266969 @default.
- W4362586919 hasRelatedWork W3166711969 @default.
- W4362586919 hasRelatedWork W4205213711 @default.
- W4362586919 hasRelatedWork W4220885170 @default.
- W4362586919 hasRelatedWork W4225380062 @default.
- W4362586919 hasRelatedWork W4280492560 @default.
- W4362586919 hasVolume "18" @default.
- W4362586919 isParatext "false" @default.
- W4362586919 isRetracted "false" @default.
- W4362586919 workType "article" @default.